Galapagos expands strategic alliance in metabolic disease with Merck & Co., Inc.
Total alliance milestones more than double to over €400 million, plus royalties on worldwide sales
16-Oct-2009 -
Galapagos NV announced that it has expanded its global strategic alliance in metabolic diseases with an affiliate of Merck & Co., Inc to incorporate the development of new therapies for atherosclerosis.
Galapagos will be responsible for the discovery and pre-clinical development of new small ...
atherosclerosis
chemistry
clinical trials
+9